Trinity Biotech | TRIB - Current Assets


Trinity Biotech reported $31.36M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Abbott USD 23.5B 1.02B Sep/2026
Bayer EUR 39.6B 5.96B Sep/2026
Bio-Rad Laboratories USD 3.08B 58.1M Sep/2026
EDAP TMS EUR 50.36M 6.01M Mar/2026
J&J USD 56.35B 3.42B Sep/2026
Mesa Laboratories USD 105.63M 8.2M Dec/2025
OraSure Technologies USD 222.94M 17.84M Jun/2026
Plus Therapeutics USD 11.77M 6.26M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Siemens EUR 65.14B 3.81B Jun/2026
Thermo Fisher Scientific USD 25.62B 2.25B Sep/2026
Tosoh JPY 848.95B 13.59B Sep/2026
Trinity Biotech USD 31.36M 4.54M Mar/2026
Veracyte USD 467.88M 106.9M Sep/2026